Allocated but not treated: the silent 16% - Authors' reply

Affiliations

¹ Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK.
² Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
³ Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. Electronic address: martin.landray@ndph.ox.ac.uk.

Comment

Peter Horby et al. Lancet. 2022.

. 2022 May 7;399(10337):1775-1776.

doi: 10.1016/S0140-6736(22)00384-1.

¹ Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK.
² Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
³ Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. Electronic address: martin.landray@ndph.ox.ac.uk.

No abstract available

Comment on

Allocated but not treated: the silent 16.
Lee TC, Morris AM, Schwartz IS, McDonald EG. Lee TC, et al. Lancet. 2022 May 7;399(10337):1775. doi: 10.1016/S0140-6736(22)00377-4. Lancet. 2022. PMID: 35526549 Free PMC article. No abstract available.

1. Pocock SJ, McMurray JJV, Collier TJ. Statistical controversies in reporting of clinical trials: part 2 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66:2648–2662. - PubMed
1. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55. - PMC - PubMed
1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed